Description

Drug Classification:

Vildagliptin and Metformin Hydrochloride (HCl) tablets belong to a class of medications known as antidiabetic agents. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Metformin is a biguanide. Together, they help improve glycemic control in patients with type 2 diabetes mellitus.

Formulations:

• Vildagliptin MS, Metformin HCl Tablets:
  • Strength: Available in two formulations:
    • Vildagliptin 50 mg / Metformin HCl 850mg Tablets (14’s)
    • Vildagliptin 50 mg / Metformin HCl 1000 mg Tablets (14’s)
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 14 tablets each, ensuring easy handling and storage.

Indications:

Vildagliptin MS, Metformin HCl Tablets are indicated for the treatment of type 2 diabetes mellitus in adults. This combination medication helps lower blood sugar levels by improving insulin secretion and sensitivity, thereby aiding in glycemic control.

Usage:

• Vildagliptin MS, Metformin HCl Tablets should be taken orally with meals to reduce the risk of gastrointestinal side effects associated with Metformin.
• It is essential to adhere to the prescribed dosage and regimen recommended by your healthcare provider.
• Regular monitoring of blood glucose levels is necessary to assess treatment efficacy and adjust dosage as needed.

Dosage:

• The dosage of Vildagliptin MS, Metformin HCl Tablets may vary depending on the patient’s individual response to treatment and glycemic control goals.
• The usual starting dose is one tablet twice daily, with gradual titration based on blood glucose levels and tolerance.
• Dosage adjustments may be necessary in patients with renal impairment or other comorbidities.

Pharmacokinetics:

• Vildagliptin is rapidly absorbed after oral administration, with peak plasma concentrations achieved within 1-4 hours.
• Metformin is also rapidly absorbed, with peak plasma concentrations reached within 2-3 hours.
• Both Vildagliptin and Metformin undergo renal elimination, with Metformin predominantly excreted unchanged in the urine.

Pharmacodynamics:

• Vildagliptin works by inhibiting the enzyme DPP-4, which inactivates incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, Vildagliptin prolongs the action of these incretins, leading to increased insulin secretion and decreased glucagon release, resulting in lower blood glucose levels.
• Metformin acts primarily by decreasing hepatic glucose production and enhancing peripheral glucose uptake, thereby lowering blood glucose levels.

Side Effects:

• Common side effects of Vildagliptin MS, Metformin HCl Tablets may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort.
• Rare but serious side effects may include lactic acidosis, particularly in patients with renal impairment or other predisposing factors.
• Contact your healthcare provider immediately if you experience severe or persistent side effects while taking Vildagliptin MS, Metformin HCl Tablets.

Experience the efficacy and safety of Vildagliptin MS, Metformin HCl Tablets from AIT Pharmaceuticals Division. Trust in our commitment to providing quality medications to improve the lives of patients with type 2 diabetes mellitus. For more information, please visit our website or consult your healthcare provider.